Inhibitor Therapeutics (INTI) Accumulated Expenses (2012 - 2026)
Inhibitor Therapeutics' (INTI) quarterly Accumulated Expenses came in at $33536.0 in Q1 2026, up 4.72% YoY from $32023.0 in Q1 2025, and down 95.14% on a QoQ basis from $690085.0 in Q4 2025.
Inhibitor Therapeutics (INTI) Accumulated Expenses (2012 - 2026) Analysis & Trends
Inhibitor Therapeutics (INTI) has 10 years of Accumulated Expenses data on file, last reported at $33536.0 in Q1 2026.
- Quarterly Accumulated Expenses rose 4.72% year-over-year to $33536.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $33536.0 (up 4.72% YoY) and the FY2025 annual result came in at $690085.0, down 0.52% from the prior year.
- Accumulated Expenses eased to $33536.0 in Q1 2026, from $690085.0 in the prior quarter.
- In the past five years, Accumulated Expenses ranged from a high of $693722.0 in Q4 2024 to a low of $7725.0 in Q2 2025.
- A 5-year average of $153310.9 and a median of $40432.0 in 2025 frame the typical range for Accumulated Expenses.
- Annual changes were most pronounced in 2023 — Accumulated Expenses jumped 414.95% — and 2025, when it tumbled 53.81%.
- Tracing INTI's Accumulated Expenses over 5 years: stood at $122621.0 in 2022, then jumped by 414.95% to $631433.0 in 2023, then rose by 9.86% to $693722.0 in 2024, then decreased by 0.52% to $690085.0 in 2025, then sank by 95.14% to $33536.0 in 2026.
- The last three Accumulated Expenses figures came in at $33536.0 (Q1 2026), $690085.0 (Q4 2025), and $40432.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Inhibitor Therapeutics | 15.64 Mn | 15.64 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 33,536.00 |
| Dec 31, 2025 | 690,085.00 |
| Sep 30, 2025 | 40,432.00 |
| Jun 30, 2025 | 7,725.00 |
| Mar 31, 2025 | 32,023.00 |
| Dec 31, 2024 | 693,722.00 |
| Sep 30, 2024 | 42,853.00 |
| Jun 30, 2024 | 16,724.00 |
| Mar 31, 2024 | 43,934.00 |
| Dec 31, 2023 | 631,433.00 |
| Sep 30, 2023 | 63,293.00 |
| Jun 30, 2023 | 32,109.00 |
| Mar 31, 2023 | 73,436.00 |
| Dec 31, 2022 | 122,621.00 |
| Sep 30, 2022 | 34,845.00 |
| Jun 30, 2022 | 27,139.00 |
| Mar 31, 2022 | 20,375.00 |
| Dec 31, 2021 | 53,000.00 |
| Sep 30, 2021 | 10,161.00 |
| Jun 30, 2021 | 5,358.00 |